Population-based analysis of invasive fungal infections, France, 2001-2010

Dounia Bitar, Olivier Lortholary, Yann Le Strat, Javier Nicolau, Bruno Coignard, Pierre Tattevin, Didier Che, Françoise Dromer, Dounia Bitar, Olivier Lortholary, Yann Le Strat, Javier Nicolau, Bruno Coignard, Pierre Tattevin, Didier Che, Françoise Dromer

Abstract

To determine the epidemiology and trends of invasive fungal infections (IFIs) in France, we analyzed incidence, risk factors, and in-hospital death rates related to the most frequent IFIs registered in the national hospital discharge database during 2001-2010. The identified 35,876 IFI cases included candidemia (43.4%), Pneumocystis jirovecii pneumonia (26.1%), invasive aspergillosis (IA, 23.9%), cryptococcosis (5.2%), and mucormycosis (1.5%). The overall incidence was 5.9/100,000 cases/year and the mortality rate was 27.6%; both increased over the period (+1.5%, +2.9%/year, respectively). Incidences substantially increased for candidemia, IA, and mucormycosis. Pneumocystis jirovecii pneumonia incidence decreased among AIDS patients (-14.3%/year) but increased in non-HIV-infected patients (+13.3%/year). Candidemia and IA incidence was increased among patients with hematologic malignancies (>+4%/year) and those with chronic renal failure (>+10%/year). In-hospital deaths substantially increased in some groups, e.g., in those with hematologic malignancies. IFIs occur among a broad spectrum of non-HIV-infected patients and should be a major public health priority.

Keywords: Invasive mycosis; Pneumocystis jirovecii; aspergillosis; candidemia; cryptococcosis; mucormycosis.

Figures

Figure 1
Figure 1
A) Trends in the incidence of invasive fungal infections in France, 2001–2010. The incidence increased (p

Figure 2

A) Invasive fungal infections in…

Figure 2

A) Invasive fungal infections in patients with hematologic malignancies (HM) in France, 2004–2010.…

Figure 2
A) Invasive fungal infections in patients with hematologic malignancies (HM) in France, 2004–2010. The case count continuously increased (pPneumocystis jirovecii pneumonia (Pjp) decreased from 468.0 to 351.5 cases/100,000 patients/year (−4.4%, p = 0.006). B) In HSCT recipients (average 4,300 cases per year, no significant trend), candidemia increased from 721.5 to 1008.6 cases (+6.0%, p = 0.05) and invasive aspergillosis from 2,573.4 to 3,705.3 cases (+9.8%, p<0.001) per 100,000 HM patients per year. C) The number of patients with solid tumors continuously increased (p<0.001), and candidemia increased among those patients from 33.7 to 40.9 cases/100,000 patients/year (+6.2%, p<0.001). D) The number of patients with chronic renal failure continuously increased (p<0.001). Candidemia increased from 57.9 to 88.6 cases/100,000 patients/year (+8.1%), IA from 7.0 to 12.0 cases/100,000 patients/year (+18.4%, p = 0.007), and Pjp increased with a peak during 2007–2008 (+11.1%, p = 0.052). E) In the HIV/AIDS population (increase p<0.001), incidence of Pjp and cryptococcosis decreased by −17.9% and −19.0%, respectively (p<0.001). HSCT, hematologic stem cell transplant.
Figure 2
Figure 2
A) Invasive fungal infections in patients with hematologic malignancies (HM) in France, 2004–2010. The case count continuously increased (pPneumocystis jirovecii pneumonia (Pjp) decreased from 468.0 to 351.5 cases/100,000 patients/year (−4.4%, p = 0.006). B) In HSCT recipients (average 4,300 cases per year, no significant trend), candidemia increased from 721.5 to 1008.6 cases (+6.0%, p = 0.05) and invasive aspergillosis from 2,573.4 to 3,705.3 cases (+9.8%, p<0.001) per 100,000 HM patients per year. C) The number of patients with solid tumors continuously increased (p<0.001), and candidemia increased among those patients from 33.7 to 40.9 cases/100,000 patients/year (+6.2%, p<0.001). D) The number of patients with chronic renal failure continuously increased (p<0.001). Candidemia increased from 57.9 to 88.6 cases/100,000 patients/year (+8.1%), IA from 7.0 to 12.0 cases/100,000 patients/year (+18.4%, p = 0.007), and Pjp increased with a peak during 2007–2008 (+11.1%, p = 0.052). E) In the HIV/AIDS population (increase p<0.001), incidence of Pjp and cryptococcosis decreased by −17.9% and −19.0%, respectively (p<0.001). HSCT, hematologic stem cell transplant.

References

    1. Patterson TF. Advances and challenges in management of invasive mycoses. Lancet. 2005;366:1013–25 . 10.1016/S0140-6736(05)67381-3
    1. Pappas PG, Alexander BD, Andes DR, Hadley S, Kauffman CA, Freifeld A, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis. 2010;50:1101–11 . 10.1086/651262
    1. McNeil MM, Nash SL, Hajjeh RA, Phelan MA, Conn LA, Plikaytis BD, et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980–1997. Clin Infect Dis. 2001;33:641–7 . 10.1086/322606
    1. Maschmeyer G. The changing epidemiology of invasive fungal infections: new threats. Int J Antimicrob Agents. 2006;27(Suppl 1):3–6 . 10.1016/j.ijantimicag.2006.03.006
    1. Dromer F, Mathoulin-Pelissier S, Fontanet A, Ronin O, Dupont B, Lortholary O; French Cryptococcosis Study Group. Epidemiology of HIV-associated cryptococcosis in France (1985–2001): comparison of the pre- and post-HAART eras. AIDS. 2004;18:555–62. 10.1097/00002030-200402200-00024
    1. Morris A, Lundgren JD, Masur H, Walzer PD, Hanson DL, Frederick T, et al. Current epidemiology of Pneumocystis pneumonia. Emerg Infect Dis. 2004;10:1713–20. 10.3201/eid1010.030985
    1. Rees JR, Pinner RW, Hajjeh RA, Brandt ME, Reingold AL. The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992–1993: results of population-based laboratory active surveillance. Clin Infect Dis. 1998;27:1138–47. 10.1093/clinids/27.5.1138
    1. Menzin J, Meyers JL, Friedman M, Korn JR, Perfect JR, Langston AA, et al. The economic costs to United States hospitals of invasive fungal infections in transplant patients. Am J Infect Control. 2011;39:e15–20. 10.1016/j.ajic.2010.06.009
    1. Lamagni TL, Evans BG, Shigematsu M, Johnson EM. Emerging trends in the epidemiology of invasive mycoses in England and Wales (1990–9). Epidemiol Infect. 2001;126:397–414. 10.1017/S0950268801005507
    1. Brown GD, Denning DW, Levitz SM. Tackling human fungal infections. Science. 2012;336:647. 10.1126/science.1222236
    1. Direction de la recherche, des études, de l'évaluation et des statistiques (DREES). Le panorama des établissements de santé, Paris: DREES; 2011.
    1. Bitar D, Morizot G, Vancauteren D, Dannaoui E, Lanternier F, Lortholary O, et al. Estimating the burden of mucormycosis infections in France (2005–2007) through a capture-recapture method on laboratory and administrative data. Rev Epidemiol Sante Publique. 2012;60:383–7. 10.1016/j.respe.2012.03.007
    1. Royston P, Ambler G, Sauerbrei W. The use of fractional polynomials to model continuous risk variables in epidemiology. Int J Epidemiol. 1999;28:964–74. 10.1093/ije/28.5.964
    1. Bitar D, Vancauteren D, Lanternier F, Dannaoui E, Che D, Dromer F, et al. Increasing incidence of zygomycosis (mucormycosis), France, 1997–2006. Emerg Infect Dis. 2009;15:1395–401. 10.3201/eid1509.090334
    1. Lanternier F, Dannaoui E, Morizot G, Elie C, Garcia-Hermoso D, Huerre M, et al. A global analysis of mucormycosis in France: the RetroZygo Study (2005–2007). Clin Infect Dis. 2012;54(Suppl 1):S35–43. 10.1093/cid/cir880
    1. Chang DC, Burwell LA, Lyon GM, Pappas PG, Chiller TM, Wannemuehler KA, et al. Comparison of the use of administrative data and an active system for surveillance of invasive aspergillosis. Infect Control Hosp Epidemiol. 2008;29:25–30. 10.1086/524324
    1. Menzin J, Meyers JL, Friedman M, Perfect JR, Langston AA, Danna RP, et al. Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients. Am J Health Syst Pharm. 2009;66:1711–7. 10.2146/ajhp080325
    1. Zilberberg MD, Shorr AF, Kollef MH. Secular trends in candidemia-related hospitalization in the United States, 2000–2005. Infect Control Hosp Epidemiol. 2008;29:978–80. 10.1086/591033
    1. Sandven P, Bevanger L, Digranes A, Haukland HH, Mannsaker T, Gaustad P. Candidemia in Norway (1991 to 2003): results from a nationwide study. J Clin Microbiol. 2006;44:1977–81. 10.1128/JCM.00029-06
    1. Poikonen E, Lyytikainen O, Anttila VJ, Koivula I, Lumio J, Kotilainen P, et al. Secular trend in candidemia and the use of fluconazole in Finland, 2004–2007. BMC Infect Dis. 2010;10:312. 10.1186/1471-2334-10-312
    1. Laupland KB, Gregson DB, Church DL, Ross T, Elsayed S. Invasive Candida species infections: a 5 year population-based assessment. J Antimicrob Chemother. 2005;56:532–7 . 10.1093/jac/dki258
    1. Asmundsdóttir LR, Erlendsdottir H, Gottfredsson M. Increasing incidence of candidemia: results from a 20-year nationwide study in Iceland. J Clin Microbiol. 2002;40:3489–92. 10.1128/JCM.40.9.3489-3492.2002
    1. Dasbach EJ, Davies GM, Teutsch SM. Burden of aspergillosis-related hospitalizations in the United States. Clin Infect Dis. 2000;31:1524–8 . 10.1086/317487
    1. Dromer F, Mathoulin-Pelissier S, Launay O, Lortholary O. Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLoS Med. 2007;4:e21. 10.1371/journal.pmed.0040021
    1. Kelley CF, Checkley W, Mannino DM, Franco-Paredes C, Del Rio C, Holguin F. Trends in hospitalizations for AIDS-associated Pneumocystis jirovecii pneumonia in the United States (1986 to 2005). Chest. 2009;136:190–7. 10.1378/chest.08-2859
    1. Maini R, Henderson KL, Sheridan EA, Lamagni T, Nichols G, Delpech V, et al. Increasing Pneumocystis pneumonia, England, UK, 2000–2010. Emerg Infect Dis. 2013;19:386–92 .
    1. Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010;50:1091–100 . 10.1086/651263
    1. Azie N, Neofytos D, Pfaller M, Meier-Kriesche HU, Quan SP, Horn D. The PATH (Prospective Antifungal Therapy) Alliance registry and invasive fungal infections: update 2012. Diagn Microbiol Infect Dis. 2012;73:293–300 . 10.1016/j.diagmicrobio.2012.06.012
    1. Horn DL, Fishman JA, Steinbach WJ, Anaissie EJ, Marr KA, Olyaei AJ, et al. Presentation of the PATH Alliance registry for prospective data collection and analysis of the epidemiology, therapy, and outcomes of invasive fungal infections. Diagn Microbiol Infect Dis. 2007;59:407–14. 10.1016/j.diagmicrobio.2007.06.008
    1. Alangaden GJ. Nosocomial fungal infections: epidemiology, infection control, and prevention. Infect Dis Clin North Am. 2011;25:201–25 . 10.1016/j.idc.2010.11.003
    1. Neblett Fanfair R, Benedict K, Bos J, Bennett SD, Lo YC, Adebanjo T, et al. Necrotizing cutaneous mucormycosis after a tornado in Joplin, Missouri, in 2011. N Engl J Med. 2012;367:2214–25. 10.1056/NEJMoa1204781
    1. Kainer MA, Reagan DR, Nguyen DB, Wiese AD, Wise ME, Ward J, et al. Fungal infections associated with contaminated methylprednisolone in Tennessee. N Engl J Med. 2012;367:2194–203. 10.1056/NEJMoa1212972
    1. Al-shair K, Atherton GT, Harris C, Ratcliffe L, Newton PJ, Denning DW. Long-term antifungal treatment improves health status in patients with chronic pulmonary aspergillosis: a longitudinal analysis. Clin Infect Dis. 2013;57:828–35 . 10.1093/cid/cit411

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera